<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352066</url>
  </required_header>
  <id_info>
    <org_study_id>AVX-102</org_study_id>
    <nct_id>NCT00352066</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together</brief_title>
  <official_title>A Phase I, Open Label, Controlled, Intra-subject Comparison Study to Investigate the Effect of Co-administration Upon the Pharmacokinetics of Tipranavir (Ritonavir Boosted) and Apricitabine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avexa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avexa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to see if apricitabine or tipranavir affect the levels of each other
      in the blood (pharmacokinetic interaction) when they are dosed together.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apricitabine is a new NRTI in development for treatment of drug resistant HIV. Tipranavir is
      a recently licensed protease inhibitor for treatment of drug resistant HIV. Tipranavir
      affects the plasma concentration of some other drugs when they are used together with
      tipranavir. This study will examine whether the pharmacokinetics of apricitabine are changed
      when it is dosed together with tipranavir compared to apricitabine alone. Also, the
      pharmacokinetics of tipranavir will be examined at steady state when it is dosed alone and
      when it is dosed together with apricitabine. Information on the safety and tolerability of
      the two drugs when dosed together will also be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the single dose pharmacokinetics of apricitabine when administered alone and in the presence of steady state concentrations of tipranavir 500 mg administered twice daily in combination with ritonavir 200 mg twice daily.</measure>
    <time_frame>day 1 and day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the steady state pharmacokinetics of tipranavir 500 mg administered twice daily with ritonavir 200mg in the presence and absence of apricitabine.</measure>
    <time_frame>day 9 and day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of apricitabine administered in combination with tipranavir and ritonavir.</measure>
    <time_frame>day 10</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apricitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy males 18-40 years old

          -  non-smokers

          -  no clinically significant medical history

        Exclusion Criteria:

          -  current or relevant previous medical history of significance

          -  hepatitis B, hepatitis C, or HIV positive

          -  current use of prescription or OTC medications

          -  use of illicit substances or alcohol (&gt;14 drinks/week)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan W Cox, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Avexa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jasper Clinic Inc</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2006</study_first_submitted>
  <study_first_submitted_qc>July 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan Cox</name_title>
    <organization>Avexa</organization>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>anti-retroviral therapy</keyword>
  <keyword>nucleoside analogue</keyword>
  <keyword>reverse transcriptase</keyword>
  <keyword>apricitabine</keyword>
  <keyword>tipranavir</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

